Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
07:30 PDT / 10:30 EDT / 15:30 BST / 16:30 CEST DNA and RNA therapeutics are drug products composed of an active genetic component linked to an efficient delivery system, generally lipid nanoparticles (LNPs). Those treatments include both prophylactic vaccines that prevent infection by triggering the patient’s immune system and therapeutic vaccines that will be used to treat and cure patients. Each therapy will require its own LNP formulation depending on the genetic material and targeted tissue.
Thursday November 3rd 2022 08:00 PDT / 11:00 EDT / 15:00 GMT / 16:00 CET Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format. Ionizable lipid nanoparticles (LNPs) have been widely used for in vivo delivery of RNA therapeutics, predominantly ending up targeting the liver (Patisiran, BNTech162b, mRNA-1273).
Gene and gene-modified cell therapy treatments have demonstrated their potential in addressing unmet medical needs across a wide variety of human diseases, including cardiovascular, neurodegenerative, ocular, immunologic disorders and cancer. These therapies are based on the delivery of corrective DNA (DeoxyriboNucleic Acid) into target cells with viral vectors.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
